MetaCap

Cardiol Therapeutics (CRDL) vs Molecular Partners (MOLN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cardiol Therapeutics (CRDL) has outperformed Molecular Partners (MOLN) over the past year, losing 11.3% versus a loss of 37.5%. Over five years, CRDL leads with a -60.1% price change compared with -77.9% for MOLN. Cardiol Therapeutics is the larger company by market cap ($110.1 million vs $96.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRDL-11.35%MOLN-37.50%
+143%+49%-46%
Nov 21, 20251 yearNov 20, 2026
CRDL-57.92%MOLN-75.84%
+219%+64%-91%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRDL versus MOLN key metrics
MetricCRDLMOLN
Share price$0.8626$2.53
Market cap$110.14M$96.80M
1-day change-2.28%-5.25%
YTD return-9.58%-42.07%
1-year return-11.35%-37.50%
5-year return-60.06%-77.87%
EPS (TTM)$-0.24$-1.68
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$2.34$5.36
52-week low$0.8417$2.52
Distance from 52-week high-63.14%-52.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+874.96%+295.64%
Average volume1.20M1.63K
Shares outstanding127.69M38.34M
Employees18134
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CRDL has outperformed MOLN by 26.2 percentage points over the past year.

About Cardiol Therapeutics

CRDL stock →

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

About Molecular Partners

MOLN stock →

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

CRDL vs MOLN FAQ

Which is bigger, Cardiol Therapeutics or Molecular Partners?

Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $110.14M compared with $96.80M for Molecular Partners (MOLN).

Which stock has performed better over the past year, CRDL or MOLN?

CRDL returned -11.35% over the past 12 months, compared with -37.50% for MOLN (price return, excluding dividends). Past performance does not predict future results.

Are Cardiol Therapeutics and Molecular Partners in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons